Zydus receives US FDA marketing nod for eletriptan hydrobromide tablets

Zydus Cadila has received the final approval from the US FDA to market eletriptan hydrobromide tablets, 20 mg (base) and 40 mg (base). The drug which is used in the treatment of migraine, will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus, us fda marketing, eletriptan hydrobromide tablets